

Synthesis of new fluorescent amino acids with triazolopyridine core: Diacids sensors ESI

L. Chiassai,^a R. Ballesteros-Garrido,^{*ab} R. Ballesteros^a and B. Abarca^a

a) Universitat de Valencia, Facultat de Farmacia Dpto Química Organica, Vicente Andres Estellés s/n 46100 Burjassot, Spain
b) I2SysBio Universitat de Valencia CSIC. C/ Catedrático Agustín Escardino, 9 46980 Paterna (Valencia) Spain

S1: Materials and Methods


S2: ^1H NMR Spectra of starting material

S3: NMR Spectra of new compounds

S1: Materials and Methods

Starting materials, if commercially available, were purchased and used as such. The solvents used were of spectroscopic or equivalent grade. When known compounds had to be prepared by literature procedures, pertinent references are given. Melting points or ranges (m.p.) given were determined on a Büchi B-545 heated stage. ^1H and (^1H decoupled) ^{13}C nuclear magnetic resonance (NMR) spectra were recorded at 300 and 75 MHz. Chemical shifts are reported in δ units, parts per million (ppm), and were measured relative to the signals for residual deuterated Chlorophorm or deuterated methanol. Coupling constants (J) are given in Hz. Coupling patterns are abbreviated as, for example, s (singlet), d (doublet), t (triplet), q (quartet), td (triplet of doublets), m (multiplet), app. s (apparent singlet) and br. (broad). COSY and DEPT/ed-HSQC experiments were performed for all compounds. IR spectra were recorded using FT-IR ATR. HRMS were recorded using TOF electro-spray ionization (ESI-positive). UV-Visible spectra were measured on an Agilent 8453 spectrometer equipped with a Peltier temperature controller system (± 0.1 °C). The emission spectra were recorded with a PTI MO- 5020 spectrofluorimeter in the 300–700 nm range.

S2: ^1H NMR Spectra of starting material



S3: NMR Spectra of new compounds

*(2S)-2-{[6-([1,2,3]triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl-amino} propanoic acid **4a**.*


*(2S)-3-Methyl-2-{[6-([1,2,3]triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]amino}butanoic acid **4b***

*(2S)-1-[6-([1,2,3]Triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl] pyrrolidine-2-carboxylic acid. **4c***

*(2S)-3-(1H-Indol-3-yl)-2-{[6-([1,2,3]triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]amino} propanoic acid. **4d***


*(2S)-3-(4-Hydroxyphenyl)-2-{[6-([1,2,3]triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]amino} propanoic acid **4e***


*(2S)-3-Phenyl-2-{[6-([1,2,3]triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl]amino}propanoic acid. **4f***



4a


MeOD-d₄






4a


MeOD-d₄






4a

MeOD-d₄



*= AcOEt #= EtOH &= Cl₃CH



4a

MeOD-d₄

&


*

#


*

*


#







*= AcOEt #= EtOH &= Cl₃CH




4b










DEPT-135






MeOD-d₄









4c



CDCl₃






4c

CDCl₃

DEPT-135




— 175.54
— 156.76
— 149.16
— 139.21
— 136.93
— 131.40
— 126.55
— 125.37
— 120.04
— 115.84
— 110.75
— 106.07


— 77.58
— 77.16
— 76.74

— 61.03


— 48.17

— 29.03
— 24.69







1D-NOE experiences with compound 4c






MeOD-d₄






4d

DMSO-d₆




Methanol




4d

DMSO-d₆

Methanol






4d


DMSO-d₆


DEPT-135



158.18
149.10
137.32
137.01
136.14
130.96
127.51
126.80
125.79
123.77
120.85
120.65
118.33
116.35
111.42
110.93
107.77

55.75
48.68
40.08
39.80
39.52
39.24
38.96
27.84





4e




MeOD-d₄


8.83
8.81
8.70
8.67

7.50
7.48
7.45
7.41
7.38
7.14
7.11
6.71
6.68
6.52
6.49




4.82
4.79
4.77


3.31
3.31
3.30
3.29
3.29
3.23
3.21
3.18
3.16
3.08
3.05
3.03
3.01







CDCl_3





CDCl₃








4e


MeOD-d₄

157.23
150.10
138.64
132.85
131.31
129.65
127.55
126.35
122.40
117.72
116.19
110.24
109.25

57.63
49.28
49.00
48.72
48.43
38.31











4f

MeOD-d₄

8.86
8.84
8.73
8.70
7.49
7.47
7.33
7.31
7.29
7.26
7.24
7.21
7.18
7.16
6.53
6.51
6.51


3.34
3.32
3.32
3.31
3.30
3.30
3.28
3.18
3.15
3.13
3.10






4f

MeOD-d₄





4f

MeOD-d₄

DEPT-135

159.37
 150.28
 139.12
 138.61
 132.87
 130.32
 129.38
 127.66
 127.56
 126.39
 122.44
 117.24
 109.26
 57.46
 49.28
 49.00
 48.72
 48.43
 39.11

